CML guidelines highlight need for TKI switch timing, choice

A review of the European LeukemiaNet guidelines on the care of patients with chronic myeloid leukaemia highlights the need for research into the timing and use of second-line and third-line tyrosine kinase inhibitors . The ELN guidelines, most recently published in 2013, are created by an international expert panel and revised every 3 years, explain Gianantonio Rosti and co-authors, from the University of Bologna in Italy, in the review published in the Annals of Hematology .
http://ift.tt/1J3Ktal